biopharmaceuticals
How Digital PCR Unlocks Scientific Possibilities
Digital PCR has emerged as a powerful new tool in research. QIAGEN takes it a step further with its robust, scalable and well-integrated nanoplate-based digital PCR system.
Avantor Launches Its Expanded Singapore Manufacturing Hub
Showcasing a new cGMP manufacturing facility and a world-class Quality Control Laboratory, Avantor's new hub is set to strengthen the region’s innovation and biopharma ecosystems.
Streamlining Robust Cell Line Development
Novel bioprocessing technologies can enable the development of robust, high-yield cell lines, supporting advances in biomedical research and pharmaceutical innovation.
Tadamitsu Kishimoto Wins 2020 Tang Prize
Tadamitsu Kishimoto of Osaka University is one of three recipients of the 2020 Tang Prize in Biopharmaceutical Sciences.
ASLAN Partners BioGenetics To Commercialize Varlitinib
ASLAN Pharmaceuticals will focus on clinical development of varlitinib while BioGenetics will obtain the necessary regulatory approvals for the use of the drug in South Korea.
Takeda Completes Acquisition Of Shire
The acquisition of Shire allows Takeda to expand its R&D efforts in four therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases.
Ascentage Pharma Secures US$150 Million In Series C Funding
Ascentage Pharma will use the funds to further their pipeline of drugs targeting apoptotic pathways for the treatment of cancer and other diseases.
CStone Pharma Completes US$260 Million Series B Funding Round
The funds raised will primarily be used for clinical development of CS1001 and other clinical stage assets, as well as attract top industry talents.
Merck Invests €40 Million In Asia
Merck has invested an additional €40 million (US$49.35 million) to build a robust manufacturing and distribution platform in Asia over a span of two years.
Synthesizing A Natural Compound That Hunts Down Cancer Stem Cells
Scientists in China have synthesized a natural cyclic compound that targets pancreatic cancer stem cells.
